1. Scrip

BMS Touts Breyanzi's Outpatient Administration As EU Approval Beckons

 
• By Ayisha Sharma

The US major won a positive opinion from the EU CHMP for Breyanzi with hopes the advantage of outpatient administration could help combat the lack of market impetus for CAR-T therapies.  

3D illustration of CAR-T cell attacking a cancer cell.
In CAR-T Therapy, The Patient's T-Cells Are Engineered Outside The Body. • Source: Alamy

Bristol Myers Squibb Company’s CAR-T therapy Breyanzi is set to enter the EU market for three lymphoma indications in advanced settings, with the firm touting outpatient administration as potentially boosting uptake in what has been a slow market.

Breyanzi (lisocabtagene maraleucel) received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B after at least two lines of therapy or whose cancer has come back. The positive opinion was issued on 28 January with the European Commission expected to deliver a final decision within 67 days

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas